Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 5/2024

25-03-2024 | COVID-19 | Research

The evolution of preexisting primary immune thrombocytopenia after COVID-19 onset: A nationally representative, prospective, multicentre, observational study

Authors: Haixia Fu, Xuan Cai, Lijuan Cui, Weixia Nong, Wenqian Li, Heng Mei, Tonghua Yang, Han Yue, Qiusha Huang, Zhuoyu An, Yejun Wu, Xiaojun Huang, Xiaohui Zhang, on behalf of the Collaborative ITP Working Group

Published in: Annals of Hematology | Issue 5/2024

Login to get access

Abstract

The symptoms in patients with primary immune thrombocytopenia (ITP) after COVID-19 onset remain largely unclear. The aim of this study was to describe the platelet count fluctuations in ITP patients following the diagnosis of COVID-19. A prospective multicentre observational study was conducted from December 15th, 2022, to January 31st, 2023 in 39 general hospitals across China. Patients with preexisting primary ITP who were newly diagnosed with COVID-19 were enrolled. A total of 1216 ITP patients with newly-diagnosed COVID-19 were enrolled. 375 (30.8%) patients experienced ITP exacerbation within eight weeks after the diagnosis of COVID-19, and most exacerbation (266/375, 70.9%) developed in the first two weeks. Immunosuppressive therapy for ITP and severe/critical COVID-19 infection were independent variables associated with ITP exacerbation. Overall the platelet count had a transient increasing trend, and the platelet peak value occurred at two weeks after COVID-19 infection. Then, the platelet count decreased to the baseline level in the following weeks. The platelet count had a transient increasing trend in ITP patients following the diagnosis of COVID-19. ITP exacerbation only occurred in less than one-third of ITP patients. Nonimmunosuppressive therapy may have an advantage to prevent ITP exacerbation during COVID-19.
Appendix
Available only for authorised users
Literature
1.
Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 181(2):271-280.e278PubMedPubMedCentralCrossRef
2.
Chen F, Zhang Y, Li X, Li W, Liu X, Xue X (2021) The Impact of ACE2 Polymorphisms on COVID-19 Disease: Susceptibility, Severity, and Therapy. Front Cell Infect Microbiol 11:753721PubMedPubMedCentralCrossRef
3.
Gusev E, Sarapultsev A, Solomatina L, Chereshnev V (2022) SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19. Int J Mol Sci 23(3):1716PubMedPubMedCentralCrossRef
4.
5.
Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y (2021) The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev 20(4):102792PubMedPubMedCentralCrossRef
6.
Huang CY, Tsai HW, Liu CY et al (2021) The predictive and prognostic role of hematologic and biochemical parameters in the emergency department among coronavirus disease 2019 patients. Chin J Physiol 64(6):306–311PubMedCrossRef
7.
8.
Bahadoram M, Saeedi-Boroujeni A, Mahmoudian-Sani MR, Hussaini H, Hassanzadeh S (2022) COVID-19-induced immune thrombocytopenic purpura. Immunopathogenesis Clin Implications Infez Med 30(1):41–50
9.
de la Cruz-Benito B, Rivas-Pollmar MI, Alvarez Roman MT et al (2021) Paradoxical effect of SARS-CoV-2 infection in patients with immune thrombocytopenia. Br J Haematol 192(6):973–977PubMedCrossRef
10.
Dainese C, Valeri F, Bardetta M et al (2022) (2022) Impact of covid-19 infection, vaccination, and serological response in immune thrombocytopenic purpura patients: A single-center global analysis. Biomedicines 10(11):2674PubMedPubMedCentralCrossRef
11.
12.
Provan D, Arnold DM, Bussel JB et al (2019) Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3(22):3780–3817PubMedPubMedCentralCrossRef
13.
Lee EJ, Beltrami-Moreira M, Al-Samkari H et al (2022) SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Blood 139(10):1564–1574PubMedPubMedCentralCrossRef
14.
15.
16.
Campbell RA, Boilard E, Rondina MT (2021) Is there a role for the ACE2 receptor in SARS-CoV-2 interactions with platelets? J Thromb Haemost 19(1):46–50PubMedCrossRef
17.
Martin JF, Slater DN, Trowbridge EA (1983) Abnormal intrapulmonary platelet production: a possible cause of vascular and lung disease. Lancet 1(8328):793–796PubMedCrossRef
18.
Hottz ED, Bozza FA, Bozza PT (2018) Platelets in Immune Response to Virus and Immunopathology of Viral Infections. Front Med (Lausanne) 5:121PubMedCrossRef
19.
20.
Rohlfing AK, Rath D, Geisler T, Gawaz M (2021) Platelets and COVID-19. Hamostaseologie 41(5):379–385PubMedCrossRef
21.
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181(2):281-292 e286PubMedPubMedCentralCrossRef
22.
23.
Nakayama K (1997) Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J 327(Pt 3):625–635PubMedPubMedCentralCrossRef
24.
Nicolai L, Massberg S (2020) Platelets as key players in inflammation and infection. Curr Opin Hematol 27(1):34–40PubMedCrossRef
25.
Perico L, Benigni A, Casiraghi F, Ng LFP, Renia L, Remuzzi G (2021) Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nat Rev Nephrol 17(1):46–64PubMedCrossRef
26.
McGonagle D, O’Donnell JS, Sharif K, Emery P, Bridgewood C (2020) Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2(7):e437–e445PubMedPubMedCentralCrossRef
27.
Rodrigues TS, de Sa KSG, Ishimoto AY et al (2021) Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients. J Exp Med 218(3):e20201707PubMedCrossRef
28.
Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G (2020) Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct Target Ther 5(1):293PubMedPubMedCentralCrossRef
29.
30.
Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D (2007) Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 109(7):2832–2839PubMedCrossRef
31.
32.
Repsold L, Joubert AM (2021) Platelet function, role in thrombosis, inflammation, and consequences in chronic myeloproliferative disorders. Cells 10(11):3034PubMedPubMedCentralCrossRef
33.
Schattner A, Kadi J, Dubin I (2019) Reactive thrombocytosis in acute infectious diseases: Prevalence, characteristics and timing. Eur J Intern Med 63:42–45PubMedCrossRef
34.
Yin S, Huang M, Li D, Tang N (2021) Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis 51(4):1107–1110PubMedCrossRef
35.
Kenya C, Bunawan NC, Nugroho HM, Harlivasari AD, Sigarlaki ED, Rinaldi I (2022) COVID-19 with extreme thrombocytosis: A case report and its possible mechanisms. Caspian J Intern Med 13(Suppl 3):289–294PubMedPubMedCentral
36.
Qu R, Ling Y, Zhang YH et al (2020) Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol 92(9):1533–1541PubMedPubMedCentralCrossRef
37.
Gnatenko DV, Liu Z, Hearing P et al (2022) Cytokine pathway variants modulate platelet production: IFNA16 is a thrombocytosis susceptibility locus in humans. Blood Adv 6(16):4884–4900PubMedPubMedCentralCrossRef
38.
Coomes EA, Haghbayan H (2020) Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev Med Virol 30(6):1–9PubMedCrossRef
39.
40.
Kaushansky K, Lok S, Holly RD et al (1994) Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 369(6481):568–571PubMedCrossRef
41.
Chen N, Zhou M, Dong X et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507–513PubMedPubMedCentralCrossRef
42.
Wang D, Hu B, Hu C et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323(11):1061–1069PubMedPubMedCentralCrossRef
43.
Lin L, Lu L, Cao W, Li T (2020) Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 9(1):727–732PubMedPubMedCentralCrossRef
44.
Qin C, Zhou L, Hu Z et al (2020) Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 71(15):762–768PubMedCrossRef
45.
Wichmann D, Sperhake JP, Lutgehetmann M et al (2020) Autopsy findings and venous thromboembolism in patients with COVID-19: A prospective cohort study. Ann Intern Med 173(4):268–277PubMedCrossRef
46.
Oxley TJ, Mocco J, Majidi S et al (2020) Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 382(20):e60PubMedCrossRef
47.
Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18(4):844–847PubMedPubMedCentralCrossRef
48.
49.
Helms J, Severac F, Merdji H, Angles-Cano E, Meziani F (2020) Prothrombotic phenotype in COVID-19 severe patients. Intensive Care Med 46(7):1502–1503PubMedPubMedCentralCrossRef
50.
Llitjos JF, Leclerc M, Chochois C et al (2020) High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 18(7):1743–1746PubMedPubMedCentralCrossRef
51.
Ren B, Yan F, Deng Z et al (2020) Extremely high incidence of lower extremity deep venous thrombosis in 48 patients with severe COVID-19 in Wuhan. Circulation 142(2):181–183PubMedCrossRef
52.
Nopp S, Moik F, Jilma B, Pabinger I, Ay C (2020) Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost 4(7):1178–1191PubMedPubMedCentralCrossRef
53.
Mao L, Jin H, Wang M et al (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 77(6):683–690PubMedCrossRef
54.
Shi S, Qin M, Shen B et al (2020) Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 5(7):802–810PubMedPubMedCentralCrossRef
Metadata
Title
The evolution of preexisting primary immune thrombocytopenia after COVID-19 onset: A nationally representative, prospective, multicentre, observational study
Authors
Haixia Fu
Xuan Cai
Lijuan Cui
Weixia Nong
Wenqian Li
Heng Mei
Tonghua Yang
Han Yue
Qiusha Huang
Zhuoyu An
Yejun Wu
Xiaojun Huang
Xiaohui Zhang
on behalf of the Collaborative ITP Working Group
Publication date
25-03-2024
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 5/2024
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-05720-0

Other articles of this Issue 5/2024

Annals of Hematology 5/2024 Go to the issue

Correspondence

Effective treatment of pleural effusion in chronic lymphocytic leukemia with acalabrutinib: a case report

Review Article

Posttransplant cyclophosphamide beyond haploidentical transplantation

Correspondence

Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?

Original Article

Cause-specific mortality in a population-level cohort of diffuse large B-cell lymphoma following chemotherapy in the early 21st century

Original Article

Epidemiological features and a survival nomogram for primary lymphoma of the male genital tract

Original Article

Prediction of severe infections in chronic lymphocytic leukemia: a simple risk score to stratify patients at diagnosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits